Although selective VIP receptor agonists have yet to be evaluated in clinical trials of PD, further research is warranted because VIP is proven in animal models of PD to change systemic immunity to a less reactive and generally more anti-inflammatory phenotype. The gene discussed is VIP; the disease is Parkinson disease.